



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**February 23<sup>rd</sup>, 2015 6:00 – 8:30 p.m.**

- |  |                    |
|--|--------------------|
| <b>1. Executive Session</b>  | <b>6:00 - 6:30</b> |
| <b>2. Introductions and Approval of DUR Board Minutes</b><br>(Public Comment Prior to Board Action)  | <b>6:30 - 6:35</b> |
| <b>3. DVHA Pharmacy Administration Updates</b> <ul style="list-style-type: none"><li>▪ Updates</li></ul>   | <b>6:35 - 6:40</b> |
| <b>4. Medical Director Update</b> <ul style="list-style-type: none"><li>▪ Clinical Programs Update</li><li>▪ Prescriber Comments</li></ul>   | <b>6:40 – 6:45</b> |
| <b>5. Follow-up Items from Previous Meetings</b> <ul style="list-style-type: none"><li>▪ Appropriate use of Asthma controller medications</li></ul>  | <b>6:45 – 7:00</b> |
| <b>6. RetroDUR/DUR</b> <ul style="list-style-type: none"><li>▪ 2016 RetroDUR Initiatives Schedule</li></ul>  | <b>7:00 – 7:20</b> |
| <b>7. Clinical Update: Drug Reviews</b><br>(Public comment prior to Board action)  | <b>7:20 – 7:45</b> |
| <b>Abbreviated New Drug Reviews</b> <ul style="list-style-type: none"><li>▪ Kalydeco® Tab (ivacaftor)</li></ul>  |                    |
| <b>Full New Drug Reviews</b> <ul style="list-style-type: none"><li>▪ Praluent® Inj (alirocumab)</li><li>▪ Repatha® Inj (evolocumab)</li></ul>  |                    |
| <b>8. Therapeutic Drug Classes – Periodic Review</b><br>(Public comment prior to Board action) <ul style="list-style-type: none"><li>▪ Ophthalmic Antibiotics</li><li>▪ Ophthalmics, Glaucoma Agents</li><li>▪ Ophthalmic Anti-Inflammatories &amp; Miscellaneous Agents</li><li>▪ Ophthalmics for Allergic Conjunctivitis</li></ul> | <b>7:45 – 8:15</b> |
| <b>9. New Managed Therapeutic Drug Classes</b>   | <b>8:15 – 8:20</b> |

(Public comment prior to Board action)

- Iron Chelating Agents

**10. Review of Newly-Developed/Revised  
Clinical Coverage Criteria and/or Preferred Products**

**8:20-8:20**

(Public comment prior to Board action)

**11. General Announcements**

**8:20 – 8:30**

**Selected FDA Safety Alerts**

Children's Guaifenesin Grape Liquid and Guaifenesin DM Cherry Liquid by Perrigo

Company: Recall - Potential Defect with Dosage Cup

[http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm481563.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm481563.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)

FDA Drug Safety Communication: FDA cautions about dosing errors when switching between different oral formulations of antifungal Noxafil (posaconazole); label changes approved

[http://www.fda.gov/Drugs/DrugSafety/ucm479352.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm479352.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)

FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines

[http://www.fda.gov/Drugs/DrugSafety/ucm476466.htm?source=govdelivery&utm\\_medium=email&utm\\_source=govdelivery](http://www.fda.gov/Drugs/DrugSafety/ucm476466.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery)

**12. Adjourn**

**8:30**